会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • OXYCODONE CONJUGATES WITH LOWER THE ABUSE POTENTIAL AND EXTENDED DURATION OF ACTION
    • 氧化还原能降低滥用潜力和延长治疗时间
    • WO2004082620A3
    • 2005-09-15
    • PCT/US2004007910
    • 2004-03-15
    • CONTROLLED CHEMICALS INC
    • SHAFER JULES ATELYATNIKOV VLADISLAV VGUO ZHIWEI
    • A61K31/485A61K47/48
    • C07D489/08A61K47/555A61K47/60
    • The abuse potential of a bioavailable drug such as an opiate analgesic agent is reduced and its duration of action is extended by converting it to a poorly absorbed ester prodrug or other prodrug derivative prior to formulation. Unlike many existing sustained release formulations of active pharmaceutical agents wherein an active pharmaceutical agent can be released by chewing, crushing, or otherwise breaking tablets or capsule beads containing the active pharmaceutical agent, such mechanical processing of tablets or capsule beads containing a prodrug of this invention neither releases the active drug nor compromises the controlled conversion of prodrug to drug. Moreover, tablets and capsule beads containing prodrugs of this invention or other drugs can be formulated with a sufficient amount of a thickening agent such as hydroxypropylmethylcellulose or carboxymethylcellulose to impede inappropriate intravenous and nasal administration of formulations that are not indicated for these modes of administration.
    • 降低生物可利用药物如鸦片止痛剂的滥用潜力,并且通过在制剂前将其转化为不良吸收的酯前药或其它前药衍生物来延长其作用时间。 与活性药物的许多现有持续释放制剂不同,其中通过咀嚼,破碎或以其它方式破坏含有活性药剂的片剂或胶囊珠可以释放活性药剂,这种包含本发明前药的片剂或胶囊珠粒的机械加工 既不释放活性药物也不妥协药物对药物的受控转化。 此外,含有本发明前药或其他药物的片剂和胶囊珠可以用足够量的增稠剂如羟丙基甲基纤维素或羧甲基纤维素配制,以阻止不适用于这些给药模式的制剂的不适当的静脉内和鼻内施用。
    • 9. 发明专利
    • DE602004024963D1
    • 2010-02-25
    • DE602004024963
    • 2004-03-15
    • CONTROLLED CHEMICALS INC
    • SHAFER JULES ATELYATNIKOV VLADISLAV VGUO ZHIWEI
    • A61K47/48A61K31/485
    • The abuse potential of a bioavailable drug such as an opiate analgesic agent is reduced and its duration of action is extended by converting it to a poorly absorbed ester prodrug or other prodrug derivative prior to formulation. Unlike many existing sustained release formulations of active pharmaceutical agents wherein an active pharmaceutical agent can be released by chewing, crushing, or otherwise breaking tablets or capsule beads containing the active pharmaceutical agent, such mechanical processing of tablets or capsule beads containing a prodrug of this invention neither releases the active drug nor compromises the controlled conversion of prodrug to drug. Moreover, tablets and capsule beads containing prodrugs of this invention or other drugs can be formulated with a sufficient amount of a thickening agent such as hydroxypropylmethylcellulose or carboxymethylcellulose to impede inappropriate intravenous and nasal administration of formulations that are not indicated for these modes of administration.